BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:28 AM | Saturday | Sep 5, 2026 Seeking Alpha

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

News Thumbnail
9:28 AM | Saturday | Sep 5, 2026 Seeking Alpha

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

News Thumbnail
10:56 AM | Friday | Sep 4, 2026 Zacks Investment Research

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

News Thumbnail
9:35 AM | Friday | Sep 4, 2026 Seeking Alpha

Bristol Myers Squibb: Still Cheap, Despite What The Chart Says

News Thumbnail
7:15 AM | Friday | Sep 4, 2026 Seeking Alpha

Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price

News Thumbnail
1:51 AM | Thursday | Sep 3, 2026 Barrons

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

News Thumbnail
12:30 PM | Wednesday | Sep 2, 2026 Fool - Investing News

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now

News Thumbnail
2:02 PM | Monday | Aug 31, 2026 24/7 Wall Street

This Popular Healthcare ETF Is Diluting Your Dividend Income

News Thumbnail
11:00 AM | Saturday | Aug 29, 2026 Business Wire

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

News Thumbnail
10:15 AM | Saturday | Aug 29, 2026 The Motley Fool

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

News Thumbnail
4:08 AM | Saturday | Aug 29, 2026 Defense World

232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC

News Thumbnail

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Seeking Alpha

9:28 AM | Saturday | Sep 5, 2026

news photo
Loading...

Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the rich cash flows delivering a secure dividend and healthier balance sheet.

Read full article redirect
9:28 AM | Saturday | Sep 5, 2026

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Seeking Alpha

Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the rich cash flows delivering a secure dividend and healthier balance sheet.

Read full article arrow
News Thumbnail
9:28 AM | Saturday | Sep 5, 2026

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Seeking Alpha

Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the rich cash flows delivering a secure dividend and healthier balance sheet.

Read full article arrow
News Thumbnail
10:56 AM | Friday | Sep 4, 2026

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Zacks Investment Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read full article arrow
News Thumbnail
9:35 AM | Friday | Sep 4, 2026

Bristol Myers Squibb: Still Cheap, Despite What The Chart Says

Seeking Alpha

Bristol Myers Squibb remains a Strong Buy, trading at a 51% discount to sector median with a compelling risk/reward profile. BMY's growth portfolio delivered 15% YoY revenue growth, offsetting headwinds from Opdivo's decline and upcoming Eliquis patent expiry. The company boasts a 3.7% forward dividend yield, robust margins, and accelerating bottom-line growth, supporting its defensive, income-generating appeal.

Read full article arrow
News Thumbnail
7:15 AM | Friday | Sep 4, 2026

Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price

Seeking Alpha

Bristol Myers Squibb remains undervalued, trading at a 9.8x forward P/E with a 3.7% yield. BMY's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting 5% YoY total revenue growth. Management raised full-year adjusted EPS guidance, with robust Eliquis growth and a strong pipeline of over 10 potential new medicines.

Read full article arrow
News Thumbnail
1:51 AM | Thursday | Sep 3, 2026

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Barrons

Technical indicators have turned bullish for the three stocks.

Read full article arrow
News Thumbnail
12:30 PM | Wednesday | Sep 2, 2026

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now

Fool - Investing News

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

Read full article arrow
News Thumbnail
2:02 PM | Monday | Aug 31, 2026

This Popular Healthcare ETF Is Diluting Your Dividend Income

24/7 Wall Street

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.

Read full article arrow
News Thumbnail
11:00 AM | Saturday | Aug 29, 2026

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).

Read full article arrow
News Thumbnail
10:15 AM | Saturday | Aug 29, 2026

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

The Motley Fool

Bristol Myers Squibb's cardiovascular drug Eliquis is set to lose patent protection in 2028. The company is busy bringing out new drugs and developing more to offset the revenue it will lose.

Read full article arrow
News Thumbnail
4:08 AM | Saturday | Aug 29, 2026

232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC

Defense World

Beacon Pointe Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 232,697 shares of the biopharmaceutical company's stock, valued at approximately $13,408,000. A number

Read full article arrow
News Thumbnail